What Veraxa Biotech AG - Post de-SPAC does.

Prior to the Business Combination, the Company did not conduct any material activities other than those incidental to its formation and the matters contemplated by the Business Combination Agreement, such as the making of certain required securities law filings. Upon the Closing, Veraxa Biotech AG merged with and into PubCo, with PubCo as the surviving company.

Information regarding the business of Veraxa is included in the Prospectus in the sections entitled “ Information About the Company ,” which is incorporated herein by reference, except that (i) the intellectual property disclosures set forth in the section entitled “ Intellectual Property ” in the Prospectus are superseded in their entirety by the updated intellectual property disclosures provided directly below and (ii) the Company Management’s Discussion and Analysis of Financial Condition and Results of Operation is presented directly in Item 5 of this Report and is not incorporated by reference.

Description: Relevant for VERAXA’s Hitmaster and microfluidics-based antibody screening technology. This patent describes a microfluidic system for detecting and sorting droplets that contain particles labeled with detectable markers. The system identifies droplets based on the presence and intensity of these markers and directs them into different channels for sorting. The method also enables quantitative binding assays, supporting high-throughput applications such as single-cell analysis, drug screening, and diagnostics

More on VRXA.

• Veraxa Biotech AG - Post de-SPAC summary
• Veraxa Biotech AG - Post de-SPAC financial statements
• Veraxa Biotech AG - Post de-SPAC key metrics
• Veraxa Biotech AG - Post de-SPAC health scores and style box
• Veraxa Biotech AG - Post de-SPAC earnings
• Veraxa Biotech AG - Post de-SPAC dividends
• Veraxa Biotech AG - Post de-SPAC valuation
• Veraxa Biotech AG - Post de-SPAC ownership and insiders
• Veraxa Biotech AG - Post de-SPAC peers

Figures from Veraxa Biotech AG - Post de-SPAC's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.